ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

IMAGE: D. Ross Camidge, MD, PhD and the ATOMIC consortium show that brigatinib remains effective even after first-line therapy with another next-generation ALK inhibitor. view more  Credit: University of Colorado Cancer Center Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK+ NSCLC). Since then, a range of next-generation ALK-inhibitors including ceritinib,…

Details

Welcome to Galaxy’s Edge

In the summer of 2015, when the Walt Disney Company unveiled plans to build monumental “Star Wars” lands at its California and Florida theme parks, a wave of euphoria washed over the planet. Bob Iger, Disney’s chief executive, made the announcement at a fan convention, revealing that one ride would allow people to pilot the…

Details